To assess clinical outcomes, efficacy, and safety according to sex during anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation.
Introduction
Atrial fibrillation (AF) is the most frequently encountered arrhythmia; it constitutes an enormous health and economic burden worldwide. The presence of AF, even in otherwise healthy individuals, is associated with increased long-term morbidity and mortality. 1 Several studies have suggested that there may be important differences in outcomes between sexes. For example, women have been found to have a higher overall risk of stroke compared with men when they develop AF. 2 -6 This is reflected in the CHA 2 DS 2 VASc risk score, where female sex is listed as a risk factor. 7 Other studies have shown that the risk of female sex may be confined only to women bearing the highest risk (i.e. CHADS 2 score ≥2) 6 or to women with more frequent cessation of anticoagulant therapy. 8 Also, neurological outcome after stroke in patients with AF appears to be worse in women compared with men. 9, 10 On the other hand, some studies have found that women may benefit more from warfarin compared with men, 9,11 despite poorer international normalized ratio (INR) control, 12 while they carry a similar or mildly increased risk of bleeding compared with men. 4, 8, 9, 13 These differences may partially be explained by differences in cardiovascular risk profiles between sexes. In general, when compared with men, women with cardiovascular disease are older and have more risk factors for stroke, more comorbidities, worse inflammatory and metabolic profiles, poorer rhythm and rate control, and more severe arrhythmic events.
14 However, these data are drawn mostly from cohort studies and registries, with their inherent limitations, including their inability to adjust for all confounders. Further elucidation of the outcomes in female and male patients with AF during treatment with oral anticoagulation is needed and can be derived from large-scale prospective clinical trials. Previous results of the large Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial suggested that the efficacy and safety of apixaban when compared with warfarin was consistent in both sexes. 15 However, differences between sexes might influence the results. Therefore, we explored further the occurrence of clinical events, as well as the efficacy and safety of apixaban compared with warfarin according to sex, in various adjustment models, in patients enrolled in the ARISTOTLE trial.
Methods

Study design
This study is a secondary analysis of data from the ARISTOTLE trial. In this trial, randomization was stratified by the investigative site and prior warfarin status (experienced, naive), and sex was not a prespecified stratified randomization criterion. The design and results of the ARISTOTLE trial have been published previously. 15, 16 The study was approved by the ethics committee at each centre, and all patients gave written informed consent prior to inclusion in the study. Briefly, the ARISTOTLE trial was conducted at 1034 centres in 39 countries between 19 December 2006 and 2 April 2010. Patients were enrolled if they had AF or atrial flutter and at least one CHADS 2 risk factor for stroke or systemic embolism (SSE). Patients were equally randomized to receive warfarin (target INR 2 -3) or apixaban. The dose of apixaban was 5 mg twice daily, or 2.5 mg twice daily for patients with at least two of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 mmol/L).
The primary efficacy endpoint of the ARISTOTLE trial was SSE. The primary safety outcome was major bleeding, which was classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as clinically overt bleeding accompanied by a decrease in the haemoglobin level of at least 2 g/dL, or transfusion of at least 2 units of packed red cells, occurring at a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal), or resulting in death. 17 The median duration of follow-up was 1. 
Outcomes
The following outcomes were assessed: (i) SSE, (ii) all-cause death, (iii) cardiovascular death, (iv) myocardial infarction, (v) hospitalization or emergency room visit for congestive heart failure, (vi) major bleeding (according to the ISTH definition), (vii) composite major or non-major clinically relevant (NMCR) bleeding (defined as bleeding not meeting the ISTH definition for major bleeding but requiring change in therapy or extended hospitalization), and (viii) net clinical benefit (NCB) defined as a composite of SSE or major bleeding. In addition, data on time in the therapeutic range (TTR) (for patients randomized to warfarin) and study drug discontinuation (for patients randomized to apixaban) were analysed.
Statistics
Baseline clinical characteristics are summarized according to sex. Categorical variables are compared for men and women by x 2 tests and are presented as percentages (counts). Continuous variables are compared by Wilcoxon rank sum tests and are presented as medians and IQRs. Event rates for outcomes are presented as total number of events (rate per 100 patient-years of follow-up). The association between sex (women vs. men) and outcomes is presented as hazard ratios (HRs) with 95% confidence intervals (CIs) from a Cox proportional hazards regression model. Patients who died from causes other than the outcomes of interest were censored at the time of death; thus, the competing risk was handled by modelling cause-specific hazards. Interactions of sex with stroke history, age category (where age was a five-level categorical variable with the following age groups: ,55, 55 -64, 65 -74, 75 -84, and .85 years), and randomized treatment were tested with Cox proportional hazards models with sex and subgroup main effects and their interaction. In models that include sex-by-age and sex-by-stroke history interactions, associations between sex (women vs. men) and outcomes are presented separately for each stroke and age subgroup. Likewise, the randomized treatment effect within each sex group was characterized by the HR (apixaban vs. warfarin) and corresponding 95% CI derived from a Cox proportional hazards model.
Models including all factors significantly associated with each endpoint were previously developed using backward selection with a ¼ 0.05 for the endpoints SSE, all-cause death, major bleeding, and myocardial infarction. We used these existing models for adjustment, after augmenting them to include additional clinically relevant variables. The demographic features, medical history, and disease characteristics that were used for adjustment are summarized in the Supplementary material online, Table S1 . As a sensitivity analysis, models were repeated adjusting each endpoint for all variables in the Supplementary material online, Table S1 and adjusting for randomized treatment. In a second sensitivity analysis, patients were censored at the time of discontinuation in order to evaluate hazards on treatment. Differences with P ≤ 0.05 (two sided) were considered statistically significant. All analyses were performed with SAS version 9.2 (SAS Institute, Inc., Cary, NC).
Results
Participants
A total of 11 785 men and 6416 women were enrolled in the ARISTOTLE trial. Baseline characteristics according to sex are summarized in Table 1 . Women were older, less likely to be smokers, and consumed less alcohol than men. Women were more likely to have paroxysmal AF and to be warfarin-naive at inclusion in the trial. They had higher CHADS 2 and CHA 2 DS 2 VASc scores ( Figure 1) , and higher prevalence of prior stroke/transient ischaemic attack/ systemic embolism, hypertension, and abnormal renal function, while men had a higher prevalence of heart failure or left ventricular dysfunction, ischaemic heart disease, and bleeding history. Women were more likely to have significant mitral regurgitation and heart failure with preserved ejection fraction, and overall the median left ventricular ejection fraction was 5% higher in women vs. men (60 vs. 55%). On the other hand, men were more likely to have left ventricular hypertrophy. Heart rate while in AF/flutter was higher in women. Women received more digoxin and calcium channel blockers, while men received more angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, b-blockers, and aspirin.
Outcomes
The rate of SSE tended to be higher in women, but after adjustment for differences in baseline characteristics, there remained no statistically significant difference between women and men. Women, compared with men, had a lower risk of all-cause death ( Figure 2 ) and cardiovascular death, with and without adjustment. The rate of myocardial infarction and hospitalization or emergency room visit for congestive heart failure were not significantly different between women and men. Overall, there was a trend towards lower risk for major or NMCR bleeding in women. Net clinical benefit was also similar between women and men ( Table 2) . The TTR for warfarin-treated patients was lower in women (median: 63.8%; IQR: 50.1 -75.4%) compared with men (median: 67.2%; IQR: 53.7 -77.0%; P , 0.0001). The study discontinuation rate was higher in women than in men, even after adjustments for covariables.
There were no significant differences in outcomes between women and men in any of the pre-specified age subgroups, with the exception of patients younger than 55 years, in whom women had higher rates of bleeding events (major and NMCR) than men.
This difference seemed to be due to low risk of bleeding in men younger than 55 years compared with all other groups (Supplementary material online, Table S2 ). Results were similar in a sensitivity analysis that censored patients at the time of study drug discontinuation and in a sensitivity analysis that adjusted each endpoint for randomized treatment and all adjustment variables shown in Supplementary material online, Table S1 .
Women with prior stroke had a 30% lower risk of recurrent SSE than men, whereas women without prior stroke had a risk similar to that of men (Supplementary material online, Table S3 ). On the contrary, women without prior stroke had a lower cardiovascular death than men, whereas women with prior stroke had a similar risk with men. All-cause death was lower in women compared with men, regardless of previous stroke history. The association of sex with myocardial infarction, hospitalization or emergency room visit for congestive heart failure, major bleeding, major and NMCR bleeding, and NCB did not differ according to previous stroke history.
Treatment effect
The superiority of apixaban over warfarin in relation to efficacy and safety was independent of sex ( Figure 3) . Thus, the risk of stroke/systemic embolism and the risk of major and NMCR bleeding were each reduced by apixaban compared with warfarin in both women and men.
Discussion
In this study, including 11 785 men and 6416 women with AF and at least one risk factor for stroke and treated with oral anticoagulants, women had a similar rate of stroke but lower mortality than men, after adjustment for the differences between sexes in baseline characteristics. Net clinical benefit was similar in both sexes, and the efficacy and safety benefits of apixaban compared with warfarin were consistent in women and men.
Baseline characteristics and risk factors
Previous studies have shown that the prevalence of AF is higher in men compared with women across all age groups. 9 In accordance with previous studies, 18, 19 in ARISTOTLE, women were older than men and had more comorbidities, which translated into higher CHADS 2 risk scores. In previous studies, women had more hypertension and diabetes but less coronary artery disease. 9, 18 Furthermore, women had more heart failure with preserved ejection fraction, whereas men had more heart failure with reduced ejection fraction. 18 Our data are consistent with these previous observations, except that the prevalence of diabetes was similar between the two sexes. Similar to prior studies, in our study, women had slightly higher heart rates than men while in AF 14 and poorer INR control. 12, 20, 21 Women were less likely to be treated with angiotensin-converting enzyme inhibitors, b-blockers, aspirin, and statins, but women were more likely to be treated with digoxin and calcium channel blockers.
Outcomes
Previous studies of AF have shown either no differences in cardiovascular morbidity and mortality between women and men 18 higher mortality in women compared with men. 6 Our data show opposite results, with and without careful adjustment for other factors that relate to death. Thus, in the ARISTOTLE trial, both all-cause and cardiovascular mortality were .35% lower in women compared with men, which might be partially explained by a trend towards less myocardial infarction and less major bleeding, and significantly less major or NMCR bleeding. In addition, the differences between our results and previous studies may be explained by differences in populations between cohort studies (which included a broad population with AF) and the ARISTOTLE study where, by design, all patients required the presence of additional risk factors for stroke, thus selecting a more homogeneous and higher-risk population. That easily could contribute to the difference by excluding 'low risk' men, that would have been included in population-based studies. Previous studies have shown that women have a higher risk of stroke when in AF, 2 -6 particularly when not anticoagulated, but this may be limited only to women at higher risk (i.e. CHADS 2 score Hazard ratio corresponds to the risk of women vs. men. CI, confidence interval; HR, hazard ratio; ER, emergency room; CHF, congestive heart failure.
a Adjusted models include the covariates listed in Supplementary material online, Table S1 .
Clinical outcomes in patients with atrial fibrillation ≥2), 6 women older than 75 years, 3 or to women with more frequent cessation of anticoagulant therapy. 8 There is considerable controversy on the possible mechanisms of the higher stroke risk reported in women compared with men. 23, 24 In ARISTOTLE, however, taking into account the higher-risk profile in women, women had rates of SSE that were similar to those in men, regardless of age. We found that women with prior stroke in our study had a 30% lower risk of recurrent stroke than men; however, this subgroup finding may have been due to chance. It is important to recognize that both CHADS 2 and CHA 2 DS 2 VASc scores were developed and validated in patients not on oral anticoagulation; in these patients, female sex was independently associated with increased risk of stroke, 25 -27 although this was not observed in younger women without other risk factors. 7 Our results suggest that female sex is not an important risk factor for stroke in chronically anticoagulated patients. These results should be further explored in large epidemiological studies, in order to verify the hypothesis that female sex might not be incorporated in the assessment of risk score of patients with AF. Similar to the data from the CARAF and AFFIRM studies, 12, 28 in ARISTOTLE, women treated with warfarin had poorer INR control compared with men. In previous studies, poorer INR control was associated with increased bleeding and stroke risk in women, 12,28 although this seems like less of a concern when INR control is strict. 22 Similarly, women were more likely to discontinue oral anticoagulation, even after adjustment. This could put women at higher risk for stroke but that was not observed in this study. In ARISTOTLE, however, bleeding risk was not increased in women, with the exception of those younger than 55 years old (who had higher risk of bleeding compared with age-matched men). In particular, men ,55 years had remarkably low bleeding event rates.
A prior subgroup analysis of the ARISTOTLE study showed that apixaban had consistent benefits over warfarin across different stroke risk scores (CHADS 2 /CHA 2 DS 2 VASc) and bleeding risk scores (HAS-BLED). 29 In addition, we have shown that the benefits of apixaban compared with warfarin for SSE, bleeding, and mortality appear similar across the range of centres and patients predicted quality of INR control. 29 In the current analysis, we now show that these benefits remain consistent irrespective of sex. While the details have not been published, the other major trials of direct-acting oral anticoagulants appear to also find consistency in the effects of the novel agents vs. warfarin with regards to stroke and systemic embolism and with regards to major bleeding (dabigatran in RE-LY, rivaroxaban in ROCKET AF, and edoxaban in ENGAGE AF-TIMI 48).
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Limitations
There are several limitations to our study. Concerning the comparison between the sexes, this study is an observational subgroup analysis of the ARISTOTLE trial. Nevertheless, this is, to the best of our knowledge, the largest published report comparing background factors and outcomes in women and men with AF during anticoagulation treatment. There were significantly fewer women than men included in our study. However, the number of women is still very large (.6000) and, therefore, a selection bias is very unlikely. One should be cautious to generalize the findings of this study, because patients from the ARISTOTLE study represent a selected group of patients; thus, our results may not be applicable to patients with other forms of AF (i.e. patients with artificial heart valves, renal failure, lone AF, etc.). Since all patients were anticoagulated, we could not address the influence of sex in a population that is not anticoagulated. Although we did not collect data on hormone-replacement therapy, the anticipated prevalence would be low given the mean age of our population, and this would be unlikely to affect our results.
Conclusions
In conclusion, in the ARISTOTLE trial of .18 000 patients including 6416 women, women had a similar rate of SSE and a lower risk of death and of clinically relevant bleeding when compared with men. The efficacy and safety benefits of apixaban compared with warfarin were consistent in men and women.
